KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - ALL HOSPITAL DEPARTMENTS

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	6743	97	3	50	71	66	59	35	89	99	99	95	91	57	94	98	71	71	-
Enterobacter sp	547	97	-	-	-	-	-	80	92	94	94	45	73	83	89	35	70	22	-
Klebsiella sp	3919	86	-	51	68	-	60	52	87	82	84	30	73	64	75	43	72	19	-
Proteus sp	392	95	3	-	-	-	78	60	68	34	100	-	94	51	-	-	-	-	-
Morganella sp	93	96	-	-	-	-	-	39	74	9	100	0	87	52	-	-	-	-	-
Citrobacter sp	240	96	-	-	-	-	-	74	96	96	96	92	88	87	-	-	-	-	-
Serratia sp	227	98	-	-	-	-	-	87	96	97	99	1	-	98	-	-	-	-	-
Salmonella sp	284	-	17	-	-	-	96	61	-	100	100	73	99	86	-	-	-	-	-
Shigella sp	9	-	0	-	-	-	68	20	-	100	100	100	100	65	-	-	-	-	-
Pseudomonas sp	2842	94	-	-	75	76	-	78	84	65	66	-	66	-	97	-	90	92	-
Acinetobacter sp	430	49	-	-	29	31	7	31	58	31	31	-	26	51	87	23	25	17	-
S. maltophilia	502	-	-	-	-	45	-	-	-	-	-	-	-	88	-	-	-	-	75

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	1730	-	-	-	-	-	92	100	54	98	100	-	-	-	91	100
MRSA	1066	-	-	-	-	-	72	0	63	81	100	-	-	-	75	100
Coag-neg Staph	866	-	-	-	-	-	51	25	23	63	100	-	-	-	87	100
Enterococcus sp	1256	58	-	-	-	43	-	-	-	-	95	-	-	-	-	75
S. pneumoniae	108	-	-	94	98	-	-	-	38	-	-	-	97	93	-	-
S. pyogenes	19	100	-	-	-	-	82	-	-	-	-	-	-	100	-	-
S. viridans	50	-	-	84	-	-	-	-	-	-	-	-	-	50	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
*C. parapsilosis	67	100	94	99	95	100	66
C. glabrata	50	96	95	98	99	100	0
C. auris	81	-	-	80	-	98	0
C. tropicalis	45	98	100	100	100	100	95
C. albicans	58	100	86	100	100	100	95
C. kefyr	4	100	100	100	-	-	-
C. lusitaniae	10	100	100	100	-	100	100
C. krusei	9	7	100	100	43	92	0
C. dubliniensis	11	10	100	100	25	100	0

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - ADULT DEPARTMENT (ICU AND NON-ICU LOCATIONS)

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	3915	97	7	51	66	61	54	28	87	99	99	94	90	53	-	98	86	50	-
Enterobacter sp	393	96	-	-	-	-	-	76	90	92	92	42	73	79	94	51	65	29	-
Klebsiella sp	2837	82	-	46	63	-	55	46	84	76	79	27	68	60	75	38	70	16	-
Proteus sp	311	94	2	-	-	-	74	53	63	34	100	0	93	45	-	-	-	-	-
Morganella sp	76	96	-	-	-	-	-	36	74	11	100	0	85	49	-	-	-	-	-
Citrobacter sp	167	95	-	-	-	-	-	72	96	95	96	95	92	87	-	-	-	-	-
Serratia sp	174	99	-	-	-	-	-	86	97	97	98	1	-	99	-	-	-	-	-
Salmonella sp	100	-	21	-	-	-	96	55	-	100	100	73	98	83	-	-	-	-	-
Shigella sp	5	-	0	-	-	-	59	17	-	100	100	100	100	50	-	-	-	-	-
Pseudomonas sp	2367	93	-	-	73	75	-	76	84	63	63	-	63	-	97	-	89	91	-
Acinetobacter sp	364	43	-	-	21	24	9	23	53	23	23	-	19	45	87	10	25	25	-
S. maltophilia	423	-	-	-	-	45	-	-	-	-	-	-	-	88	-	-	-	-	70

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	1119	-	-	-	-	-	91	99	56	98	100	-	-	-	92	100
MRSA	743	-	-	-	-	-	69	0	61	81	100	-	-	-	76	100
Coag-neg Staph	683	-	-	-	-	-	51	25	22	63	100	-	-	-	87	100
Enterococcus sp	996	52	-	-	-	37	-	-	-	-	95	-	-	-	-	71
S. pneumoniae	53	-	-	93	99	-	-	-	49	-	-	-	94	91	-	100
S. pyogenes	8	100	-	100	-	-	100	-	-	-	-	-	-	100	-	-
S. viridans	53	-	-	90	-	-	-	-	-	-	-	-	-	66	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
*C. parapsilosis	47	100	97	99	96	100	81
C. glabrata	43	95	97	97	100	100	0
C. auris	77	-	-	78	-	98	0
C. tropicalis	27	97	100	100	100	100	97
C. albicans	44	100	89	100	100	100	91
C. kefyr	4	100	100	100	-	-	-
C. krusei	9	7	100	100	43	92	0
C. dubliniensis	8	13	100	100	50	-	-

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:

Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER 2024 - PEDIATRIC DEPARTMENT (ICU AND NON-ICU LOCATIONS)

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	318	97	2	42	62	54	49	38	89	100	100	96	85	51	-	96	90	84	-
Enterobacter sp	40	100	-	-	-	-	-	89	92	99	100	61	63	87	-	-	-	-	-
Klebsiella sp	177	98	-	48	62	-	56	53	92	93	93	39	85	54	-	84	87	50	-
Proteus sp	15	100	49	-	-	-	86	86	86	15	100	-	100	96	-	-	-	-	-
Morganella sp	5	100	-	-	-	-	-	75	75	0	100	50	100	75	-	-	-	-	-
Citrobacter sp	5	100	-	-	-	-	-	94	100	96	100	50	100	100	-	-	-	-	-
Serratia sp	17	100	-	-	-	-	-	96	100	92	96	0	-	96	-	-	-	-	-
Salmonella sp	45	-	34	-	-	-	95	64	-	100	100	74	99	80	-	-	-	-	-
Shigella sp	1	-	0	-	-	-	0	0	-	50	50	50	50	0	-	-	-	-	-
Pseudomonas sp	170	100	-	-	77	79	-	88	90	75	79	-	73	-	100	-	93	96	-
Acinetobacter sp	29	96	-	-	86	82	0	87	89	88	89	-	82	87	-	-	-	-	-
S. maltophilia	41	-	-	-	-	-	-	-	-	-	-	-	-	99	-	-	-	-	92

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	179	-	-	-	-	-	90	100	45	100	100	-	-	-	89	100
MRSA	121	-	-	-	-	-	71	0	67	80	100	-	-	-	60	100
Coag-neg Staph	63	-	-	-	-	-	39	10	10	38	100	-	-	-	81	100
Enterococcus sp	51	62	-	-	-	63	-	-	-	-	97	-	-	-	-	68
S. pneumoniae	16	-	-	100	100	-	-	-	31	-	-	-	100	100	-	100
S. pyogenes	2	50	-	50	-	-	50	-	-	-	-	-	-	50	-	-
S. viridans	7	-	-	66	-	-	-	-	-	-	-	-	-	22	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
*C. parapsilosis	21	100	89	100	95	100	34
C. tropicalis	7	50	50	50	50	50	50
C. albicans	16	100	84	100	100	100	100
C. lusitaniae	10	100	100	100	-	-	50

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - ADULT ONCOLOGY DEPARTMENT

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	91	94	6	43	63	57	50	29	86	98	99	94	85	62	-	100	100	0	-
Enterobacter sp	8	90	-	-	-	-	-	88	100	90	90	43	58	78	-	-	-	-	-
Klebsiella sp	65	93	-	29	54	-	40	47	94	83	88	34	59	32	100	54	89	22	-
Proteus sp	3	100	-	-	-	-	100	100	100	50	100	-	100	100	-	-	-	-	-
Morganella sp	6	100	-	-	-	-	-	0	70	50	100	0	-	100	-	-	-	-	-
Citrobacter sp	5	50	-	-	-	-	-	30	50	50	50	50	40	30	-	-	-	-	-
Serratia sp	6	84	-	-	-	-	-	100	100	100	100	0	-	100	-	-	-	-	-
Salmonella sp	2	-	0	-	-	-	100	100	-	100	100	100	100	100	-	-	-	-	-
Shigella sp	0	-	0	-	-	-	0	0	-	0	0	0	0	0	-	-	-	-	-
Pseudomonas sp	87	81	-	-	60	59	-	61	67	52	54	-	50	-	-	-	-	-	-
Acinetobacter sp	5	84	-	-	75	84	-	84	84	59	50	-	59	100	-	-	-	-	-
S. maltophilia	19	-	-	-	-	0	-	-	-	-	-	-	-	100	-	-	-	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	27	-	-	-	-	-	97	100	47	100	100	-	-	-	86	100
MRSA	17	-	-	-	-	-	82	0	70	92	100	-	-	-	88	100
Coag-neg Staph	7	-	-	-	-	-	34	17	9	25	100	-	-	-	42	100
Enterococcus sp	58	34	-	-	-	30	-	-	-	-	88	-	-	-	-	70
S. pneumoniae	0	-	-	0	0	-	-	-	0	-	-	-	0	0	-	0
S. pyogenes	0	0	-	0	-	-	0	-	-	-	-	-	-	0	-	-
S. viridans	1	-	-	50	-	-	-	-	-	-	-	-	-	50	-	50

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
C. parapsilosis	1	100	100	100	100	100	100
C. glabrata	3	100	50	100	100	100	0
C. auris	2	-	-	100	100	100	0
C. tropicalis	0	0	0	0	0	0	0
C. albicans	4	100	100	100	100	100	100

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used.

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - PEDIATRIC ONCOLOGY DEPARTMENT

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	23	98	3	40	48	48	47	21	94	100	100	98	59	30	-	-	-	-	-
Enterobacter sp	2	100	-	-	-	-	-	100	100	100	100	100	50	100	-	-	-	-	-
Klebsiella sp	13	93	0	43	51	41	43	49	89	100	93	41	96	33	-	-	-	-	-
Proteus sp	0	0	-	-	-	-	0	0	0	0	0	-	0	0	-	-	-	-	-
Morganella sp	0	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-	-	-
Citrobacter sp	0	0	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-	-	-
Serratia sp	0	0	-	-	-	-	-	0	0	0	0	0	-	0	-	-	-	-	-
Salmonella sp	8	-	0	-	-	-	50	17	-	100	100	50	100	75	-	-	-	-	-
Shigella sp	0	0	-	-	-	-	0	0	-	0	0	0	0	0	-	-	-	-	-
Pseudomonas sp	8	100	-	-	84	84	-	100	100	75	84	-	67	-	-	-	-	-	-
Acinetobacter sp	5	100	-	-	100	88	-	100	100	100	100	-	88	100	-	-	-	-	-
S. maltophilia	4	-	-	-	-	0	-	-	-	-	-	-	-	100	-	-	-	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	15	-	-	-	-	-	92	94	54	100	100	-	-	-	53	100
MRSA	16	-	-	-	-	-	69	0	69	42	100	-	-	-	59	100
Coag-neg Staph	9	-	-	-	-	-	50	17	22	17	100	-	-	-	67	100
Enterococcus sp	7	65	-	-	-	65	-	-	-	-	100	-	-	-	-	100
S. pneumoniae	2	-	-	100	100	-	-	-	0	-	-	-	100	100	-	100
S. pyogenes	0	0	-	0	-	-	0	-	-	-	-	-	-	0	-	-
S. viridans	8	-	-	74	-	-	-	-	-	-	-	-	-	0	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
C. tropicalis	0	0	0	0	0	0	0

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - OUTPATIENT DEPARTMENT

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	1315	99	6	68	85	81	75	49	94	100	100	97	97	67	-	-	-	-	-
Enterobacter sp	26	100	-	-	-	-	-	89	97	100	100	61	86	92	-	-	-	-	-
Klebsiella sp	398	100	-	80	92	-	88	81	98	99	100	44	93	87	-	-	-	-	-
Proteus sp	13	100	37	-	-	-	100	100	84	59	100	-	100	58	-	-	-	-	-
Morganella sp	1	100	-	-	-	-	-	0	0	0	100	0	100	0	-	-	-	-	-
Citrobacter sp	36	100	-	-	-	-	-	84	96	100	100	88	100	98	-	-	-	-	-
Serratia sp	7	100	-	-	-	-	-	100	100	100	100	0	-	100	-	-	-	-	-
Salmonella sp	25	-	25	-	-	-	86	73	-	100	100	83	100	92	-	-	-	-	-
Shigella sp	1	-	0	-	-	-	100	0	-	100	100	100	100	100	-	-	-	-	-
Pseudomonas sp	54	99	-	-	97	97	-	91	100	95	94	-	93	-	-	-	-	-	-
Acinetobacter sp	15	95	-	-	100	90	0	95	100	100	100	-	100	100	-	-	-	-	-
S. maltophilia	0	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	0

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	38	-	-	-	-	-	96	100	61	100	100	-	-	-	96	100
MRSA	14	-	-	-	-	-	86	0	86	72	100	-	-	-	93	100
Coag-neg Staph	3	-	-	-	-	-	100	100	50	100	100	-	-	-	100	100
Enterococcus sp	61	98	-	-	-	90	-	-	-	-	97	-	-	-	-	100
S. pneumoniae	2	-	-	100	100	-	-	-	100	-	-	-	100	100	-	100
S. pyogenes	0	0	-	0	-	-	0	-	-	-	-	-	-	0	-	-
S. viridans	0	-	-	0	-	-	-	-	-	-	-	-	-	0	-	0

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
C. parapsilosis	0	0	0	0	0	0	0
C. glabrata	0	0	0	0	0	0	0
C. auris	0	-	-	0	0	0	0
C. albicans	0	0	0	0	0	0	0
Candida sp	0	0	0	0	0	0	0

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER 2024 - EMERGENCY DEPARTMENT

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	2843	97	3	53	73	69	62	36	90	100	100	95	93	59	-	100	84	41	-
Enterobacter sp	117	95	-	-	-	-	-	83	93	96	96	36	75	88	84	44	82	34	-
Klebsiella sp	1098	94	-	60	76	69	68	59	93	92	93	35	85	68	78	48	69	20	-
Proteus sp	181	93	2	-	-	-	78	65	85	37	100	-	96	54	-	-	-	-	-
Morganella sp	32	94	-	-	-	-	-	39	70	13	100	0	71	54	-	-	-	-	-
Citrobacter sp	78	99	-	-	-	-	-	69	99	100	100	96	95	91	-	-	-	-	-
Serratia sp	46	96	-	-	-	-	-	79	98	100	98	3	-	98	-	-	-	-	-
Salmonella sp	138	-	4	-	-	-	98	61	-	100	100	69	100	97	-	-	-	-	-
Shigella sp	4	-	0	-	-	-	50	25	-	100	100	100	100	75	-	-	-	-	-
Pseudomonas sp	504	99	-	-	92	92	-	82	79	83	84	-	84	-	-	-	-	-	-
Acinetobacter sp	43	73	-	-	45	63	67	54	36	64	64	-	50	67	75	50	100	100	-
S. maltophilia	18	-	-	-	-	0	-	-	-	-	-	-	-	90	-	-	-	-	43

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	533	-	-	-	-	-	93	100	59	99	100	-	-	-	90	100
MRSA	318	-	-	-	-	-	79	0	64	78	100	-	-	-	76	100
Coag-neg Staph	362	-	-	-	-	-	58	33	28	76	100	-	-	-	90	100
Enterococcus sp	276	78	-	-	-	71	-	-	-	-	98	-	-	-	-	89
S. pneumoniae	54	-	-	95	96	-	-	-	75	-	-	0	96	93	-	100
S. pyogenes	8	100	-	100	-	-	72	-	-	-	-	-	-	100	-	-
S. viridans	35	-	-	89	-	-	-	-	-	-	-	-	-	61	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
C. parapsilosis	2	100	100	100	100	100	100
C. glabrata	6	100	100	100	100	100	0
C. auris	0	-	-	0	0	0	0
C. tropicalis	1	100	100	100	100	100	100
C. albicans	6	100	100	100	100	100	100

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwan
Supervisor

Approved by: Dr. Sameera Al Johani
Department Head

KING ABDULAZIZ MEDICAL CITY-RIYADH
MINISTRY OF NATIONAL GUARD HEALTH AFFAIRS
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
MICROBIOLOGY SECTION

ANTIBIOGRAM REPORT FOR JAN TO DECEMBER YEAR 2024 - KASCH BUILDING

Total Number of Isolates Tested Relative to the Percentage of Susceptibility Results

ORGANISMS	TOTAL # OF ISOL TESTED	AMIKACIN	AMPICILLIN	CEFAZOLIN	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	IMIPENEM	MEROPENEM	*NITROFURANTOIN	PIP/TAZO	TRIMETH/SULFA	**COLISTIN BMD	**TIGECYCLINE	**CAZ/AVI	**CEFTO/TAZO	Levofloxacin
		S	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S
Escherichia coli	1241	98	3	47	71	64	57	36	91	99	99	95	88	51	-	97	92	55	-
Enterobacter sp	118	98	-	-	-	-	-	84	96	96	97	47	58	81	-	75	94	20	-
Klebsiella sp	731	93	-	49	67	-	59	47	90	86	86	29	72	54	91	48	81	34	-
Proteus sp	73	96	2	-	-	-	91	85	84	31	100	-	100	69	-	-	-	-	-
Morganella sp	26	100	-	-	-	-	-	41	79	8	100	0	100	49	-	-	-	-	-
Citrobacter sp	33	97	-	-	-	-	-	66	100	94	97	91	80	77	-	-	-	-	-
Serratia sp	43	98	-	-	-	-	-	92	92	98	100	0	-	100	-	-	-	-	-
Salmonella sp	151	-	18	-	-	-	96	59	-	100	100	73	99	83	-	-	-	-	-
Shigella sp	2	-	0	-	-	-	100	0	-	100	100	100	100	50	-	-	-	-	-
Pseudomonas sp	496	95	-	-	78	77	-	83	86	71	73	-	70	-	98	-	-	-	-
Acinetobacter sp	56	77	-	-	56	59	0	64	74	58	58	-	53	64	84	75	-	-	-
S. maltophilia	122	-	-	-	-	-	-	-	-	-	-	-	-	92	-	-	-	-	79

ORGANISMS	TOTAL # OF ISOL TESTED	AMPICILLIN	CEFAZOLIN	CEFOTAXIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	OXACILLIN	ERYTHROMYCIN	GENTAMICIN	LINEZOLID	MEROPENEM	MOXIFLOXACIN	PENICILLIN	TRIMETH/SULFA	VANCOMYCIN
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
MSSA (S. aureus)	473	-	-	-	-	-	91	100	52	98	100	-	-	-	88	100
MRSA	291	-	-	-	-	-	73	0	65	81	100	-	-	-	68	100
Coag-neg Staph	124	-	-	-	-	-	52	23	18	61	100	-	-	-	80	100
Enterococcus sp	340	35	-	-	-	31	-	-	-	-	93	-	-	-	-	68
S. pneumoniae	53	-	-	95	96	-	-	-	26	-	-	-	100	92	-	100
S. pyogenes	9	100	-	100	-	-	86	-	-	-	-	-	-	100	-	-
S. viridans	51	-	-	76	-	-	-	-	-	-	-	-	-	47	-	100

ORGANISMS	TOTAL # OF ISOL TESTED	FLUCYTOSINE	VORICONAZOLE	AMPHOTERICIN B	CASPOFUNGIN	MICAFUNGIN	FLUCONAZOLE
		S	S	S	S	S	S
*C. parapsilosis	28	100	93	100	100	100	41
C. glabrata	12	94	78	90	94	100	0
C. auris	8	-	-	88	100	100	0
C. tropicalis	9	100	100	100	100	100	100
C. albicans	20	100	87	100	100	100	100
C. kefyr	4	100	100	100	0	0	0

LEGEND:

S Susceptible I INTERMEDIATE

\- Not Tested/ Not Reported
* Done on Urine Isolates Only
** Done on Multi-drug Resistant Organisms

NOTE:
Yeast susceptibility is performed only on sterile samples.
Fluconazole against Candida parapsilosis is Dose-Dependent and considered susceptible only if higher dose is used

Prepared by: Fayz Alasmari
Medical Technologist II

Reviewed by: Bassam Al Alwani
Supervisor

Approved by: Dr. Sabeera Al Johani
Department Head